Staff Publications

Staff Publications

  • external user (warningwarning)
  • Log in as
  • language uk
  • About

    'Staff publications' is the digital repository of Wageningen University & Research

    'Staff publications' contains references to publications authored by Wageningen University staff from 1976 onward.

    Publications authored by the staff of the Research Institutes are available from 1995 onwards.

    Full text documents are added when available. The database is updated daily and currently holds about 240,000 items, of which 72,000 in open access.

    We have a manual that explains all the features 

Record number 440118
Title No effect of n-3 fatty acids on high-sensitivity C-reactive protein after myocardial infarction: The Alpha Omega Trial
Author(s) Hoogeveen, E.K.; Geleijnse, J.M.; Kromhout, D.; Giltay, E.J.
Source European Journal of Preventive Cardiology 21 (2014)11. - ISSN 2047-4873 - p. 1429 - 1436.
Department(s) Nutrition and Disease
Publication type Refereed Article in a scientific journal
Publication year 2014
Keyword(s) soluble adhesion molecules - coronary-heart-disease - necrosis-factor-alpha - cardiovascular risk - fish-oil - docosahexaenoic acid - inflammatory markers - serum concentrations - supplementation - men
Abstract Background Persistent inflammation plays a role in the pathogenesis of atherosclerosis. n-3 Fatty acids may have anti-inflammatory effects. This study examined the effect of plant-derived alpha-linolenic acid (ALA) and marine n-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on high-sensitivity C-reactive protein (hsCRP), a systemic marker of (low-grade) inflammation. Design/Methods A supplementary study in the Alpha Omega Trial: a multicenter, double-blind, randomized, placebo-controlled trial of low-dose n-3 fatty acids. Patients were enrolled from 2002 to 2006 and followed for 40 months. A total of 2425 patients, aged 60–80 years (79% men), with a history of myocardial infarction, were randomly assigned to margarines supplemented with a targeted additional intake of 400¿mg/day EPA and DHA, 2¿g/day ALA, EPA-DHA plus ALA, or placebo for 40 months. Results Patients consumed on average 19.8¿g margarine/day, providing an additional amount of 238¿mg/day EPA with 158¿mg/day DHA, 1.98¿g/day ALA, or both, in the active treatment groups. In the placebo group, the geometric mean hsCRP (95% confidence interval (CI)) was 1.84¿mg/l (95% CI: +1.70 to +2.00) at baseline and 1.98¿mg/l (95% CI: 1.82 to 2.15) after 40 months (p¿
There are no comments yet. You can post the first one!
Post a comment
Please log in to use this service. Login as Wageningen University & Research user or guest user in upper right hand corner of this page.